ActiTrexx
Company Details
Status: Private
Employees: 11-50
Location:
Mainz, Germany
Type:
sample
Technology:
sample
sample
sample
About: ActiTrexx GmbH is a new biotech start up and was founded in 2020. Our vision is to offer a curative cellular therapy to prevent inflammatory reactions in conditions like GvHD, solid organ transplantation and autoimmune diseases.
Regulatory T cells (Treg) - natural guardian cells of the immune system - are the key players of our cell-based drug product. Isolated Treg are activated ex vivo via specific methods and administered to patients intravenously. Unlike other comparable approaches, activated Treg (ATreg) will not be expanded in vitro, protecting them against a possible loss of function. Thus, ATreg is a safe and efficient treatment option for transplanted patients preventing and providing substantial decrease of GvHD severity and related mortality as well. The founders of ActiTrexx GmbH combine many years of unique experience in basic research, biotechnology, clinical application and pharmaceutical development. The management team is supported and complemented by a strong network of collaborators, advisors and key opinion leaders as well as experienced managers.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
ActiTrexx | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.